Recap: UroGen Pharma Q3 Earnings
Portfolio Pulse from Benzinga Insights
UroGen Pharma (NASDAQ:URGN) reported Q3 earnings with an EPS of $-0.68, beating estimates by 20.0% against an expected $-0.85. Revenue increased by $4.75 million compared to the same period last year. The company had previously beaten EPS estimates last quarter, which led to a 4.48% rise in share price the following day. Historical earnings and revenue figures were also provided for the past four quarters.
November 14, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma reported a positive earnings surprise with a 20% beat on EPS estimates and a significant increase in revenue compared to the previous year. Historical data shows a positive share price reaction to past earnings beats.
Given the earnings beat and the historical positive reaction of URGN's stock price to past earnings surprises, it is likely that the stock will experience a short-term increase in price. The 20% beat on EPS and the year-over-year revenue growth are significant positive indicators for investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100